CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $11.36B, above the global median of $1.15B
- FinancialsAltman Z-Score 5.92: safe zone
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
11.36BUSDvs all stocks (USD)
Trailing P/E
38.33xRevenue (TTM)
2.90BUSDvs all stocks (USD)
Profit Margin
10.44%Beta
1.11xvs all stocks
52-Week Change
-41.61%vs all stocks
Market Capitalization
11.36BUSDvs all stocks (USD)
Enterprise Value
11.90BUSDvs all stocks (USD)
Trailing P/E
38.33xForward P/E
20.37xPEG Ratio
0.2396xPrice to Sales (TTM)
3.92xPrice to Book (MRQ)
8.72xEnterprise to Revenue
4.10xEnterprise to EBITDA
19.76xGross Margin
69.46%Profit Margin
10.44%Operating Margin
16.03%Return on Assets (TTM)
9.74%Return on Equity (TTM)
23.00%Revenue (TTM)
2.90BUSDvs all stocks (USD)
Revenue per Share (TTM)
41.28USDUpdated Jul 19, 2026Quarterly Revenue Growth
33.90%Gross Profit (TTM)
2.06BUSDvs all stocks (USD)
EBITDA (TTM)
636.00MUSDvs all stocks (USD)
Net Income (TTM)
302.80MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
157.30%Operating Cash Flow (TTM)
619.30MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
253.38MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
2.71BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
768.20MUSDFY2025 · Dec 31, 2025Gross Profit
1.94BUSDFY2025 · Dec 31, 2025Operating Income
473.80MUSDvs all stocks (USD)
Pre-tax Income
339.50MUSDFY2025 · Dec 31, 2025Income Tax Expense
92.40MUSDFY2025 · Dec 31, 2025Net Income
247.10MUSDFY2025 · Dec 31, 2025EBIT
398.90MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
600.70MUSDFY2025 · Dec 31, 2025Research & Development
301.10MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
1.17BUSDFY2025 · Dec 31, 2025Non-operating Interest Income
34.70MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
59.40MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
247.10MUSDFY2025 · Dec 31, 2025Operating Cash Flow
374.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
716.10MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
247.10MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
90.40MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
62.20MUSDFY2025 · Dec 31, 2025Stock-based Compensation
62.70MUSDFY2025 · Dec 31, 2025Other Non-cash Items
13.20MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-140.20MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
49.20MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.60MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-27.80MUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Other Investing Activity
-3.30MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.30MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
506.10MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.21BUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-59.60MUSDFY2025 · Dec 31, 2025Other Financing Charges
-26.10MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-793.80MUSDFY2025 · Dec 31, 2025Shares Outstanding
69.26MSharesUpdated Jul 19, 2026Float Shares
68.98MSharesUpdated Jul 19, 2026Shares Short
4.85MSharesUpdated Jul 19, 2026Short Ratio
3.05daysvs all stocks
Short % of Shares Outstanding
7.91%vs all stocks
% Held by Insiders
0.33%vs all stocks
% Held by Institutions
104.93%vs all stocks
Total Cash (MRQ)
480.40MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.94USDUpdated Jul 19, 2026Total Debt (MRQ)
1.01BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.7784xCurrent Ratio (MRQ)
2.49xBook Value per Share (MRQ)
18.81USDUpdated Jul 19, 2026Total Assets
3.19BUSDvs all stocks (USD)
Total Current Assets
1.91BUSDFY2025 · Dec 31, 2025Total Liabilities
1.68BUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.28BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
995.00MUSDFY2025 · Dec 31, 2025Total Current Liabilities
680.10MUSDFY2025 · Dec 31, 2025Cash
138.70MUSDFY2025 · Dec 31, 2025Cash Equivalents
577.40MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
716.10MUSDFY2025 · Dec 31, 2025Accounts Receivable
511.30MUSDFY2025 · Dec 31, 2025Inventory
452.60MUSDFY2025 · Dec 31, 2025Accounts Payable
75.00MUSDFY2025 · Dec 31, 2025Short-term Debt
18.40MUSDFY2025 · Dec 31, 2025Other Current Liabilities
113.80MUSDFY2025 · Dec 31, 2025Long-term Debt
930.80MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
64.20MUSDFY2025 · Dec 31, 2025Common Stock (Book)
100.00KUSDFY2025 · Dec 31, 2025Retained Earnings
287.40MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.52BUSDvs all stocks (USD)
Treasury Stock
60.40MUSDFY2025 · Dec 31, 202552-Week Low
138.79USDUpdated Jul 19, 202652-Week High
354.88USDUpdated Jul 19, 202652-Week Change
-41.61%vs all stocks
Beta
1.11xvs all stocks
50-Day MA
153.02USDUpdated Jul 19, 2026200-Day MA
239.55USDUpdated Jul 19, 2026Avg 10-Day Volume
1.29MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.52MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
4.28USDUpdated Jul 19, 2026Other Income / Expense
-109.60MUSDFY2025 · Dec 31, 20258 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Is this company growing?
Multi-Year Revenue And Profit Growth
Revenue and earnings have both grown steadily across six years.
Reads
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Drawdown With OCF Coverage And Growth Consistency
Well below its peak, with cash covering profit and growth that has been steady.
Reads
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Where is this company structurally exposed?
Sharp Decline With Volume And Volatility Expansion
A steep fall on heavy volume, leaving the price far below its peak.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.34Receivables vs revenue divergence: 2.37
Financial Health
Altman Z-Score 5.92: safe zoneNotable
Altman Z-Score: 5.92
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $11.36B, above the global median of $1.15BNotable
Market cap (USD): 11,363,562,277Global Median: 1,146,734,693.424
Revenue is $2.9B, above the global median of $520.53MNotable
Revenue (USD): 2,900,800,000Global Median: 520,528,949.311
Levered free cash flow is $253.38M, above the global median of $16.24MNotable
Levered free cash flow (USD): 253,375,008Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Biomarin Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
CSPC Pharmaceutical Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Recordati Industria Chimica e Farmaceutica S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Haisco Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sichuan Kelun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Axsome Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cytokinetics, Incorporated
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cipla Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Summit Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hangzhou Fortune Gas Cryogenic Equipment Co., Ltd.
6 interpretationsOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthClose Below 40W SMA With ProfitabilityDrawdown With OCF Coverage And Growth ConsistencyPrice Below Mean With Profitability And Book ValueMulti-Year Revenue And Profit Growth
Qingdao Daneng Environment Co., Ltd.
6 interpretationsOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthClose Below 40W SMA With ProfitabilityDrawdown With OCF Coverage And Growth ConsistencyPrice Below Mean With Profitability And Book ValueMulti-Year Revenue And Profit Growth
Motomotion China Corp.
4 interpretationsOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthPrice Below Mean With Profitability And Book ValueMulti-Year Revenue And Profit Growth